Tyloxapol: Difference between revisions

{{Short description|Pharmaceutical drug}}

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 376126506

| IUPAC_name = formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol

| image = Tyloxapol.png

| width = 150

<!--Clinical data-->

| tradename =

| Drugs.com = {{drugs.com|international|tyloxapol}}

| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->

| pregnancy_US = <!-- A / B / C / D / X -->

| pregnancy_category =

| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->

| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->

| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->

| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->

| legal_status =

| routes_of_administration =

<!--Pharmacokinetic data-->

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

<!--Identifiers-->

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 25301-02-4

| ATC_prefix = R05

| ATC_suffix = CA01

| PubChem = 71388

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB06439

| ChemSpiderID = None

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = Y27PUL9H56

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D03261

| ChEBI = 141517

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201548

<!--Chemical data-->

| chemical_formula = (C₁₅H₂₁O(C₂H₄O)_m)_n

| molecular_weight = variable

'''Tyloxapol''' is a nonionic liquid [[polymer]] of the alkyl aryl polyether alcohol type. It is used as a [[surfactant]] to aid [[liquefaction]] and removal of mucopurulent{{citation needed|date=December 2013}} (containing [[mucus]] and [[pus]]) bronchopulmonary secretions,<ref>{{cite journal | vauthors = Sehgal SS, Ewing CK, Richards T, Taeusch HW | title = Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study | journal = Journal of the National Medical Association | volume = 86 | issue = 1 | pages = 46–52 | date = January 1994 | pmid = 8151722 | pmc = 2607653 }}</ref><ref>{{cite journal | vauthors = Rubin BK, Ramirez O, King M | title = Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy | journal = Chest | volume = 101 | issue = 4 | pages = 1080–5 | date = April 1992 | pmid = 1555424 | doi = 10.1378/chest.101.4.1080 }}</ref> administered by inhalation through a [[nebulizer]]<ref>{{cite web | work = Drugs.com | url = https://www.drugs.com/dict/tyloxapol.html | title = Tyloxapol definition }}</ref> or with a stream of oxygen.

With [[intraperitoneal injection]], tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of [[triglyceride]]-rich [[lipoprotein]]s. This mechanism is used to induce experimental [[hyperlipidemia]] in animals.<ref>{{cite journal | vauthors = Kourounakis AP, Victoratos P, Peroulis N, Stefanou N, Yiangou M, Hadjipetrou L, Kourounakis PN | title = Experimental hyperlipidemia and the effect of NSAIDs | journal = Experimental and Molecular Pathology | volume = 73 | issue = 2 | pages = 135–8 | date = October 2002 | pmid = 12231215 | doi = 10.1006/exmp.2002.2449 }}</ref>

Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an expectorant designated for inhalation and instillation reaching the upper and lower airways.

Other brand names of pharmaceutical products containing Tyloxapol are Exosurf and Alevaire.

== References ==

{{reflist}}

[[Category:Phenol ethers]]